❤️ Spotlight on EchoGo® Heart Failure for HFpEF detection EchoGo® Heart Failure leverages advanced AI and cardiac imaging to identify patients with Heart Failure with Preserved Ejection Fraction (HFpEF). It provides diagnostic outputs that assist healthcare professionals in diagnosing, managing, and optimizing treatment responses for patients. The technology has been scientifically validated in peer-reviewed journals, demonstrating its efficacy in improving the detection and supporting diagnosis of this challenging subtype of heart failure. Discover the latest research and use cases: ❤️ Clinical Deployment of Ultromics EchoGo® HFpEF Algorithm at Northwestern https://hubs.la/Q02H5rzh0 ❤️Comparison of an Artificial Intelligence Heart Failure Detection Model and Clinical Prediction Models in Patients with Heart Failure with Preserved Ejection Fraction (HFpEF) at Beth Israel Deaconess Medical Center and Harvard Medical School https://hubs.la/Q02H5xF_0 ❤️ Unmasking HFpEF with Artificial Intelligence: A Disruptive Opportunity for Disease Detection. https://hubs.la/Q02H5V0_0 ❤️ Automated Echocardiographic Detection of Heart Failure With Preserved Ejection Fraction Using Artificial Intelligence. https://hubs.la/Q02H5FbY0 ❤️Artificial Intelligence to Aid Early Detection of Heart Failure With Preserved Ejection Fraction https://hubs.la/Q02H5GWt0 ❤️ Association of a Novel, Non-invasive AI Model to Automate Echocardiographic Detection of Heart Failure with Preserved Ejection Fraction (HFpEF) with Invasive Hemodynamics. https://hubs.la/Q02H5KRX0 #EchoGo #Ultromics #HFpEF #HeartFailure #Cardiology #AIinHealthcare #Innovation
Ultromics
Hospitals and Health Care
Oxford, Oxfordshire 6,010 followers
Ultromics is transforming the detection of heart failure using artificial intelligence for echocardiography.
About us
Ultromics pioneers precision heart failure detection. Our groundbreaking platform, EchoGo®, is revolutionizing the diagnosis of heart failure using artificial intelligence and cardiac ultrasound. Our technology empowers clinicians to make precise, efficient, and accurate assessments, drawing from the largest known heart disease dataset in echocardiography. We target challenging cardiac diseases, starting with HFpEF, to support timely diagnosis and early intervention. In collaboration with the Mayo Clinic, Johnson & Johnson, and Pfizer, we are continuously developing innovative diagnostic tools aimed at halting the progression of heart failure. Learn more: https://www.ultromics.com/. Follow Ultromics on social media for the latest news, X: https://x.com/ultromics, LinkedIn: https://www.linkedin.com/company/ultromics/.
- Website
-
https://www.ultromics.com/
External link for Ultromics
- Industry
- Hospitals and Health Care
- Company size
- 51-200 employees
- Headquarters
- Oxford, Oxfordshire
- Type
- Privately Held
- Founded
- 2017
- Specialties
- Artificial Intelligence, Machine Learning, Healthcare, Cardiovascular Diagnosis, Diagnostic Tools, Medical Device, and Medical Imaging
Products
![Click here to view EchoGo® Heart Failure]()
EchoGo® Heart Failure
Clinical Decision Support Systems (CDSS)
The only AI powered diagnostic to detect HFpEF from a single apical 4 chamber view. EchoGo® Heart Failure offers superior diagnostic performance with improved sensitivity and specificity for HFpEF and reclassifies 64% of indeterminate HFpEF diagnoses. EchoGo® Heart Failure Features Exclusive AI-Powered Diagnostics: The only AI-powered echo-based diagnostic. Proven to detect HFpEF and support diagnosis. Single View Disease Detection: Detects HFpEF from a single 4-chamber view. Improved Diagnostic Performance: Excels in discriminating HFpEF patients and predicting higher mortality, more often than clinical scores. Proven: Detects HFpEF with 89% sensitivity and 86% specificity. JACC Advances (AI-HFpEF I), Journal of Cardiac Failure (AI-HFpEF II) Automated: Automatically delivers insights in less than 15 minutes, from image sent to report received. EchoGo® Heart Failure is now reimbursable Outpatient settings $284.88 per visit Inpatient settings $1,023.75 per stay
Locations
-
Primary
Get directions
Oxford, Oxfordshire OX1 1JD, GB
Employees at Ultromics
Updates
-
Ultromics reposted this
Professor at FAU Erlangen-Nürnberg and Reader in Medical Image Computing at Imperial College London
Fully synthetic datasets are becoming a reality. We show how to make them in Hadrien Reynaud et al.'s latest #MICCAI24 paper. Such datasets promise to solve significant data-sharing challenges in medicine by ensuring complete patient privacy, as it contains no data from real patients. Funded by European Research Council (ERC), Ultromics, UKRI Centre in AI for Healthcare (AI4Health), Deutsche Forschungsgemeinschaft (DFG) - German Research Foundation, NHR-Verein, NHR-Alliance, and Markus Blume's Hightech Agenda Bavaria. 📜 Read the Paper: https://lnkd.in/eZvmiHpY 🐍 Access the code, model weights and synthetic datasets: https://lnkd.in/eGfKgF9y 🤗 Try our interactive demo on HuggingFace: https://lnkd.in/eArw9sH6
PhD student in AI for Healthcare at Imperial College London | GenAI | Computer Vision
🚨 Our latest research on data generation and privacy preservation in medical data has been early-accepted at #MICCAI2024 ! 🚀 And the generation process 120x faster than last year ! ⭐️ Project Highlight of EchoNet-Synthetic: This novel work introduces a privacy-preserving video generation method that allows for the safe sharing of medical data. By leveraging advanced latent image/video diffusion models, we can generate precisely controlled and infinitely long echocardiograms. Our robust re-identification filter ensures that no synthetic video is overly similar to actual patient data, effectively preventing data memorization. Impact and Innovations: Our approach stands to push forward data privacy in medical imaging and beyond: 1. It ensures no real patient samples are used, maintaining total privacy. 2. The high quality of synthetic datasets permits effective training of downstream tasks, fostering broader data sharing and enhancing reproducibility in medical imaging research. We believe this work can enable wider sharing of currently private datasets and allow greater reproducibility of many works in the field of Medical Imaging. Finally, I’m grateful for the guidance of my supervisor, Bernhard Kainz, and the collaboration of all my co-authors, especially Qingjie Meng and Mischa Dombrowski. Explore Our Work: 📜 Read the Paper: https://lnkd.in/eZvmiHpY 🐍 Access the code, model weights and synthetic datasets: https://lnkd.in/eGfKgF9y 🤗 Try our interactive demo on HuggingFace: https://lnkd.in/eArw9sH6
-
-
Ultromics reposted this
This one has been a very long journey and I’m glad to have been able to help Ross Upton, PhD is some small way and thrilled to announce that the PROTEUS trial and Cardiac Amyloid Classifier, the latest step in our AI for echo work, has made a significant milestone with late breaker and hotline presentation at the European Society of Cardiology (ESC) Congress! PROTEUS is a multicentre, two-arm, randomised controlled trial evaluating the impact of introducing EchoGo, an AI platform, into the standard care pathway for echocardiology. I would like to thank all the sites and collaborators! #ClinicalResearch #AIinHealthcare #ESC2024 #PROTEUSTrial #EchoGo #InnovationInMedicine #HealthcareAI Let's continue to push the boundaries of medical science and improve patient outcomes together!
On behalf of The PROTEUS Trial Investigators, I'm thrilled to announce that I'll be presenting the primary trial results at the European Society of Cardiology Congress 2024, as a Hotline, Late Breaking Trial! Gary Woodward Paul Leeson Ashley Akerman We also have a second late breaking trial(!) for our Amyloidosis detection algorithm, presented by Patricia Pellikka, MD , in close collaboration with Jeremy Slivnick, Roberto Lang and Will Hawkes. For further details please see press release below: https://lnkd.in/e3xb2JRW Ultromics Cardiovascular Clinical Research Facility Mayo Clinic University of Chicago
-
Ultromics reposted this
On behalf of The PROTEUS Trial Investigators, I'm thrilled to announce that I'll be presenting the primary trial results at the European Society of Cardiology Congress 2024, as a Hotline, Late Breaking Trial! Gary Woodward Paul Leeson Ashley Akerman We also have a second late breaking trial(!) for our Amyloidosis detection algorithm, presented by Patricia Pellikka, MD , in close collaboration with Jeremy Slivnick, Roberto Lang and Will Hawkes. For further details please see press release below: https://lnkd.in/e3xb2JRW Ultromics Cardiovascular Clinical Research Facility Mayo Clinic University of Chicago
EchoGo® Featured in Hot Line and Late-Breaking Science Sessions at ESC Congress 2024
ultromics.com
-
📣 Ultromics to present two Late-Breakers at ESC Congress 2024! Ultromics is set to unveil significant advancements in cardiovascular care at at ESC Congress in London next month, including an ESC Hot Line Session, Late-Breaking Science session, and two abstract presentations. These presentations will showcase the latest data from our EchoGo® platform in AI-driven cardiac diagnostics. Join us at ESC Congress 2024 in London from August 30 to September 2, 2024, to witness these significant advancements in person. Hot Line Session: PROTEUS: A Prospective Randomized Controlled Trial Evaluating The Use Of Artificial Intelligence in Stress Echocardiography 🗣️Ross Upton, PhD., Ultromics, University of Oxford 📆 Monday, September 2, 3:15 PM (BST) 📍Main Auditorium Late-Breaking Science Session: Echocardiographic Screening for Cardiac Amyloidosis Using Artificial Intelligence: A Multi-Site Study for Algorithm Training and External Validation 🗣️Patricia Pellikka, MD., Mayo Clinic 📆Sunday, September 1, 9:00 AM (BST) 📍San Marino Room Abstract Posters: 🗣️Ambarish Pandey, M.D, MSCS, FAHA., UT Southwestern Medical Center. Poster Title: Diagnostic and Prognostic Evaluation of an Echocardiography-based Artificial Intelligence Algorithm for Detecting HFpEF: A Case-Control Analysis 📆 Friday, 30 August, 11:00 AM (BST) 📍 Moderated ePosters, Station 2 Poster Title: Performance of an Automated Echocardiographic Artificial Intelligence Model for Detecting Subclinical Heart Failure with Preserved Ejection Fraction (HFpEF) in Community-dwelling Older Adults 📆 Saturday, 31 August, 5:00 PM (BST) 📍 Moderated ePosters, Station 2 Read more here: https://lnkd.in/e3xb2JRW #ESCCongress #Ultromics #EchoGo #AIinHealthcare #Innovation #AIDiagnostics #HeartFailure #HeartHealth #Heathcare #HFpEF #Amyloidosis #Cardiology #EchoFirst #Echocardiography
-
-
Ultromics reposted this
☑️ Ultromics’ AI-powered heart failure detection tool, EchoGo Heart Failure, secures a new CPT code to facilitate adoption. ☑️ Signum Surgical wins FDA de novo clearance for its BioHealx implant for treating anal fistula. ☑️ Endospan Ltd. secures $25 million in funding to pursue FDA approval for its NEXUS Stent Graft System. ☑️ Spectral AI reaches enrollment goal for its burn imaging study, aiming for approval prospects in 2025. ☑️ ZAP Surgical Systems, Inc. completes first patient brain tumor treatments using its ZAP-X platform, providing non-invasive stereotactic radiosurgery. #InsightswithSmarteeva #Medtech #complaintmanagement #Pharma #Smarteeva #biotech #medtechtrends #medtechindustry #medicaltechnology #technology #health #medicaldevicediagnostics #ai #mdr #recalls #complaints #mir #fda #cvr
-
Ultromics reposted this
"This recognition by the AMA underscores the significant impact our technology is having in the field of heart failure care," said Ross Upton, PhD, Chief Executive Officer and founder of Ultromics. ❤️🩹Congratulations on this significant milestone!
📣 Breaking News on #HFpEF Reimbursement! The American Medical Association (AMA) has issued a Category III CPT® code for reimbursing EchoGo® Heart Failure. The new code, 0932T, is the only artificial intelligence CPT code specific to supporting HFpEF diagnosis through echocardiography. The code will take effect on January 1, 2025, and will replace the previous HCPCS outpatient code, C9786. This significant milestone marks a crucial advancement in enhancing the accessibility of Ultromics' ground-breaking technology in hospital outpatient settings, and underscores the impactful role EchoGo® Heart Failure plays in diagnosing HFpEF. Read the full press release here: https://hubs.la/Q02F0nbh0 #EchoGo #HeartFailure #Ultromics #Cardiology #EchoFirst
Ultromics granted CPT III reimbursement code for EchoGo® Heart Failure
ultromics.com
-
Ultromics reposted this
Well done to Ross Upton, PhD and team for achieving this huge milestone and for completing this challenging journey to secure reimbursement for a new technology, navigating through intricate policies, extensive documentation, and appeals. The new CPT code marks a pivotal step for EchoGo Heart Failure, ultimately benefiting patients, payors, and healthcare systems: Key Highlights: - New CPT Code 0932T: Streamlines reimbursement, replacing the prior HCPCS outpatient code C9786. - Enhanced Detection: Demonstrated 88% sensitivity and 82% specificity in diagnosing HFpEF, outperforming standard clinical practices. - Broad Coverage: Already covered under the NTAP code XXE2X19 for inpatient settings and received FDA 510(k) clearance in December 2022.
Ultromics’ AI-powered heart failure detection tool secures new CPT code
finance.yahoo.com